Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shire's Ornskov Maps Out Future Prospects Post- Baxalta Merger

Executive Summary

Shire's Danish chief executive says completing the Baxalta merger will greatly boost the group's exposure to longer acting orphan drugs, bring critical mass and de-risk its current asset mix with new portfolio products; a view widely shared by investors and analysts.

Advertisement

Related Content

Shire's Ornskov On Goals And Accomplishments One Year After Baxalta Merger
Shire's Record Year Bolstered By Baxalta, But Shows Across-The-Board Growth
Ocaliva PBC Uptake May Be Slow, But Builds Capital For NASH
Ocaliva PBC Uptake May Be Slow, But Builds Capital For NASH
Ocaliva OK'd; Will NASH Success, Acquisition Be Next For Intercept?
Shire & Baxalta Seal The Deal
Shire Outlines Baxalta Integration Strategy
Shire Seeking 'Tuck-in' Rather Than Large-Scale M&A As It Integrates Dyax And Baxalta
Shire Could Get More Out Of OPUS-3 Than Refiling Lifitegrast
Shire Uses Foresight to Expand in Ophthalmology

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC065341

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel